奎硫平与氯丙嗪治疗首发精神分裂症的临床对照研究  

Comparison Study on Treatment of Primary Schizophrenia with Quetiapine and Chlorpromazine

作　　者：张伟[1] 马俊国[1] 徐富玲[1] 

机构地区：[1]大庆市精神卫生中心,黑龙江大庆163000

出　　处：《黑龙江医学》2006年第2期81-82,共2页Heilongjiang Medical Journal

摘　　要：目的论证奎硫平治疗精神分裂症的疗效及安全性。方法将病程在2年以内,本次入院前未经过系统治疗的分裂症患者随机分为奎硫平组(28例)和氯丙嗪组(33例),进行对照观察研究。疗程为8周。疗效指标包括阳性和阴性症状量表(PANSS),临床总体印象量表(CGI)。不良反应指标为副反应量表(TESS)及有关实验室检查。结果临床有效率两组间无显著差异。对阴性症状实验组较对照组好(P<0.05);不良反应实验组较对照组少,且轻微。结论国产奎硫平治疗分裂症疗效可靠,安全性高,依从性好,是一种有效的抗精神病药物。Objective To discuss the curative effect and safety of quetiapine in treating primary schizophrenia. Methods There were 28 cases of PS patient treated with quetiapine as therapy group and other 33 cases PS patient were treated with chlorpromazine as control group. The results of PANSS, CGI, TESS and lab were observed after a course of 8 weeks. Results There was no significant difference between two groups. The negative symptom was better and less side effect in therapy group than those in control group. Conclusion Quetiapine aright be more reliable and safe drug to treat PS with good compliance and curative effect.

关 键 词：精神病学 分裂症 奎硫平 氯丙嗪 

分 类 号：R749.3[医药卫生—神经病学与精神病学]